Brain scan study aims to personalize Alzheimer's treatment
NCT ID NCT07152418
Summary
This study is testing whether the antibody drug lecanemab helps control Alzheimer's disease progression better than standard treatments. Researchers will follow 120 patients with early Alzheimer's or mild cognitive impairment to see who benefits most from continued treatment. Using brain scans, they aim to identify which patients should continue antibody therapy even as their symptoms progress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.